Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Hims & Hers falls -14.6%
Hims & Hers (HIMS) is down -14.6%, or -$3.25 to $19.00. Published first on TheFly – the ultimate source for real-time, ...
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today released a white paper ...
Ozempic and Wegovy considered ‘available’ after more than 2 years in shortage
The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...
Cautious Hold Rating for Hims & Hers Health Amid Strong GLP-1 Revenue Growth and Potential Long-term Risks
Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Hims Says Weight-Loss Shot ‘Just as Safe’ as Ozempic and Wegovy
Hims is pushing back on the idea that compounded injections aren’t as safe or beneficial as the brand-name drugs sold by Novo and Eli Lilly & Co., even as those companies turn to the courts and the ...
bovnews2d
HIMS’s Unexpected Surge: What’s Next?
Needham has recently initiated Hims & Hers Health Inc (HIMS) stock to Buy rating, as announced on August 22, 2024, according to Finviz. Earlier, on August 9, 2024, Imperial Capital had reduced the ...
news.stocktradersdaily8d
(HIMS) Long Term Investment Analysis
Check the time stamp on this data. Updated AI-Generated Signals for Hims & Hers Health Inc. Class A (HIMS) available here: ...